MIR19A (MicroRNA 19a)

In summary, new miRNA signatures of relevance in B-AL and B-Ly could be recognized in this study. Studies in larger cohorts are required to further validate these findings.

This review provides a comprehensive overview of the current and future applications of liquid biopsy in TNBC management, highlighting its potential to improve early disease detection, optimize therapeutic strategies, and refine patient classification. Integrating liquid biopsy into routine clinical practice could lead to better treatment outcomes and more personalized approaches to TNBC care.

Our findings suggest that elevated levels of miR-19a-3p in the serum of patients with HER2 + metastatic breast cancer may result from effective NK cell-mediated ADCC and activation of CD4 + Th1 cells, which could be responsible for the anti-tumor immune response associated with a favorable prognosis. Blood levels of miR-19a-3p might help identify breast cancer patients who have effective trastuzumab-induced anti-tumor immune responses.

Reduced CD4+ T cell enrichment in the TME predicted poor survival in HBV+ DLBCL. Down-regulation of miR-19a-3p by HBx activated the BAMBI-mediated Wnt signalling, amplifying TGF-β1 secretion to suppress anti-tumour activity of CD4⁺ T cells. The TGF-B1/TGFBR2 pair mediated the HBV+ DLBCL-CD4+ T cell communication. Targeting TGF-β or miR-19a-3p improved CD4+ T cell immunity to suppress HBV+ DLBCL progression.

However, 8-isoprostane levels were significantly lower in patients (6.68 pg/mL; interquartile range &lsqb;IQR]: 1.57-26.55) compared to controls (37.20 pg/mL, IQR: 18.55-167.58) (p < 0.001). Considering our findings in conjunction with existing literature, miR-98 appears to be a promising candidate biomarker for food allergy.

Multivariate analysis confirmed miR-200c as an independent predictor of resistance (OR: 20.90; 95% CI: 1.54-283.73). Conclusions This pilot study identifies circulating miR-19a, miR-21, and miR-200c as novel biomarkers for poor NAC response in GC, providing a foundation for personalized treatment strategies.

Our findings demonstrate that miRNA sponges targeting the miR-17/92 cluster can effectively disrupt MYC dosage compensation, leading to selective cytotoxicity in MYC-amplified cancer cells.

Combined preoperative DCE-MRI and TMEM51-AS1 testing may be used to predict the risk of postoperative recurrent metastasis in patients with TNBC. TMEM51-AS overexpression may repress TNBC progression by miR-19a-3p, which may guide the subsequent clinical management and improve the survival of TNBC patients.

The results highlighted the association of the miRNA-17-92 cluster with BC, with miR-17-5p, miR-18a-5p, miR-19a-3p, and miR-20a-5p (members of this cluster) being upregulated in the tumoral tissue and correlated with muscle invasion and tumor grading. Taken together, our study identified a panel of 26 dysregulated miRNAs in BC, some of which may be associated with aggressiveness and the risk of progression of this malignancy.

Through gene ontology enrichment analysis, we further elucidated the biological processes and pathways impacted by these miRNAs, providing insight into their contributions to CRC. The literature review did not identify any previously reported shared connection between these miRNAs, adiponectin signaling, and CRC pathogenesis.